Layer, Chiang, et al. Genome Biology
Helicos Reiterates Dx Strategy as Product Revenues, Cash Dry Up
As of Aug. 11, Helicos held $3.7 million in cash and cash equivalents — down from $6.2 million as of June 30. The company said that it will need to raise "significant additional capital" before the end of the third quarter in order to continue operations.
New to GenomeWeb? Register here quickly.